TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9628449
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (70 U/kg bolus followed by infusion of 15 U/kg per hour)
Study: 9628449
Drug: Enoxaparin (fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (fixed-dose SC enoxaparin 60 mg every 12 hours for patients ≤65 kg, 40 mg every 12 hours for patients <65 kg)
Study: 8051381
Drug: malotilate 1500
Normalized name: Maltol
Approvals — FDA: no, EMA: no, PMDA: no
Description: malotilate 1500 mg/day
Study: 8051381
Drug: malotilate 750
Normalized name: Maltol
Approvals — FDA: no, EMA: no, PMDA: no
Description: malotilate 750 mg/day
Study: 20034170
Drug: Oxazepam (60-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam (60-120 mg daily)
Study: 31997704
Drug: Nasal administration
Normalized name: Novel Influenza-H1N1-09, live virus for nasal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal administration of vasopressin (AVP)
Study: 21288628
Drug: EE 20
Normalized name: AcidFree 200mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE 20 μg/drsp 3mg COC (n=451)
Study: 19473905
Drug: Standard physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physical therapy (Gp B)
Study: 17093248
Drug: Rabbit antithymocyte
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabbit antithymocyte globulin (1.5 mg/kg daily for 5 days)
Study: 11172151
Drug: Intracoronary radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary radiation therapy with iridium-192
Study: 9506734
Drug: Troglitazone (200‐800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (200‐800 mg daily)
Study: 2454038
Drug: Cladosporium immunotherapy
Normalized name: CLADOSPORIUM
DrugBank: Cladosporium herbarum (DB10865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cladosporium immunotherapy
Study: 1073187
Drug: alexidine dihydrochloride
Normalized name: Exidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: alexidine dihydrochloride oral rinse
Study: 1073187
Drug: placebo oral
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo oral rinse
Study: 24486163
Drug: Hospital-at-home treatment
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital-at-home treatment
Study: 19936767
Drug: Chronomodulated chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronomodulated chemotherapy
Study: 16336029
Drug: Tulobuterol (2mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tulobuterol (2mg once-daily applied as a patch)
Study: 16336029
Drug: Salmeterol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (50 microg per inhalation, twice a day)
Study: 11882468
Drug: Milk consumption
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk consumption (mean 50 g/day, 95% CI 44-55 g/day)
Study: 11882468
Drug: Milk consumption
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk consumption (varied by region: rural 9 g/day, suburban 36 g/day, urban 83 g/day)
Study: 10612357
Drug: Tiagabine (TGB;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine (TGB; Gabitril) at doses of 32 mg/day and 56 mg/day
Study: 10612357
Drug: Tiagabine (TGB;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine (TGB; Gabitril) administered twice, three times, and four times daily
Study: 2278377
Drug: Continuous morphine
Normalized name: morphine sulfate Oral Suspension [MST Continus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous morphine application (0.5-1.0 microgram/kg per min)
Study: 2278377
Drug: Bolus morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus morphine injections (0.05 mg/kg)
Study: 6118666
Drug: Intra-articular yttrium-90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular yttrium-90 (5 mCi) plus steroid (triamcinolone hexacetonide, 20 mg)
Study: 6118666
Drug: Saline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline plus steroid (control)
Study: 30291016
Drug: Multimodality weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodality weight gain prevention intervention (10 weekly peer-support sessions)
Study: 25041234
Drug: Ranolazine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine (500 mg twice a day for 8 weeks)
Study: 24713310
Drug: Tapentadol sustained-release
Normalized name: tapentadol Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol sustained-release (SR) [average daily dose 433 (31) mg]
Study: 22797188
Drug: 35 mg
Normalized name: papain 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg of risedronate weekly
Study: 15969759
Drug: Calcium-fortified beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-fortified beverage (1,125 mg Ca++/d)
Study: 9718289
Drug: D-cycloserine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-cycloserine (500 mg)
Study: 7663789
Drug: Full 24-hour
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full 24-hour lung function profile (thirteen 2-hourly measurements)
Study: 2758900
Drug: Intrapartum saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapartum saline amnio-infusion
Study: 2758900
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no amnio-infusion)
Study: 435349
Drug: Suxamethonium infusion
Normalized name: suxamethonium
DrugBank: Succinylcholine (DB00202)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suxamethonium infusion at 0.25 mg s‐1 to 20 mg s‐1
Study: 435349
Drug: 30-mg i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-mg i.v. bolus dose of Suxamethonium
Study: 29240541
Drug: Metastasis-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metastasis-directed therapy (MDT)
Study: 21714697
Drug: Extended letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended letrozole regimen (5 mg/day during the first 5 days of cycle and 2.5 mg/day during the subsequent 3 days) combined with HPuFSH-GnRHant protocol
Study: 21714697
Drug: Short letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short letrozole regimen (2.5 mg/day from cycle day 3-7) combined with HPuFSH-GnRHant protocol
Study: 12201832
Drug: 10, 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10, 15 or 20 mg of pegvisomant
Study: 11793023
Drug: rosiglitazone, 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone, 8 mg/day (n = 15)
Study: 24316262
Drug: Telaprevir 1125
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir 1125 mg twice daily
Study: 20194386
Drug: No bleaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: No bleaching treatment (controls)
Study: 17394960
Drug: Isosorbide‐5‐mononitrate (IS‐5‐MN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide‐5‐mononitrate (IS‐5‐MN) 120 mg once daily for 7 days
Study: 17394960
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (24 mg/min) during intra-arterial coinfusion after IS‐5‐MN therapy
Study: 16240937
Drug: Diazepam (DZ;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (DZ; 10 mg/d) for 14 days
Study: 12167793
Drug: Corline Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corline Heparin Surface with standard dose of systemic heparin
Study: 12167793
Drug: Corline Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corline Heparin Surface with high dose of systemic heparin
Study: 12167793
Drug: Corline Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corline Heparin Surface with low dose of systemic heparin
Study: 12167793
Drug: Uncoated surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncoated surface with standard dose of systemic heparin
Study: 8591104
Drug: Danazol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (400 mg/day orally for 4 to 6 months)
Study: 27216835
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of ketamine
Study: 20735290
Drug: Eltrombopag 50
Normalized name: eltrombopag 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 50 mg
Study: 20642544
Drug: Eltrombopag 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 150 mg
Study: 7524016
Drug: Auditory treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auditory treatment
Study: 7524016
Drug: Kinesthetic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesthetic treatment
Study: 7524016
Drug: Visual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visual treatment
Study: 3215041
Drug: Intravenous alifedrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alifedrine 20 mg
Study: 3215041
Drug: Intravenous alifedrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alifedrine 40 mg
Study: 3215041
Drug: Oral alifedrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral alifedrine 40 mg
Study: 31276430
Drug: Caregiver-reported preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caregiver-reported preventive medication use
Study: 31276430
Drug: Preventive medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive medication availability at home
Study: 22854293
Drug: Medication sharing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication sharing
Study: 31276430
Drug: Filled a
Normalized name: Prefilled Applicator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filled a preventive medication in the past year (subset with pharmacy records)
Study: 31276430
Drug: Preventive medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive medication at home (subset with pharmacy records)
Study: 31276430
Drug: Caregiver report
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caregiver report of no preventive medication use in the past 2 weeks
Study: 31870325
Drug: Low-dose high-frequency
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose high-frequency clinical mentorship in EmONC
Study: 28508306
Drug: Brimonidine Tartrate
Normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brimonidine Tartrate 0.1% ophthalmic solution
Study: 28508306
Drug: Timolol Maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol Maleate 0.5% ophthalmic solution
Study: 21962451
Drug: Intravenous alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alendronate (125 μg)
Study: 21962451
Drug: Oral alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alendronate (35 mg)
Study: 21962451
Drug: Both intravenous
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both intravenous and oral alendronate
Study: 18974581
Drug: Oral calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcitriol for eight weeks
Study: 12827224
Drug: Raloxifene plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene plus MFP (60 mg/day raloxifene HCl and 20 mg/day fluoride ions)
Study: 12827224
Drug: MFP alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFP alone (20 mg/day fluoride and placebo)
Study: 11096443
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus adjuvant gene therapy during surgery
Study: 11096443
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (surgical resection and radiotherapy)
Study: 10326536
Drug: ALM +
Normalized name: SlowMag Calm + Sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALM + BCG (1 mg ALM mixed with BCG)
Study: 7661605
Drug: Thalidomide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (100 mg/d)
Study: 766798
Drug: R &
Normalized name: R & C
Approvals — FDA: no, EMA: no, PMDA: no
Description: R & S 218‐M 0.56 mg/70 kg
Study: 766798
Drug: R &
Normalized name: R & C
Approvals — FDA: no, EMA: no, PMDA: no
Description: R & S 218‐M 0.35 mg/70 kg
Study: 766798
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate 10.5 mg/70 kg
Study: 6789777
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied chemotherapeutic drugs (e.g., thiotepa, fluorouracil, betamethasone valerate)
Study: 6789777
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied chemotherapeutic drugs
Study: 19434360
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day ilaprazole
Study: 19434360
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day ilaprazole
Study: 19434360
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (ilaprazole and omeprazole)
Study: 18693810
Drug: Natural Language
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural Language Processing methods to detect trends in medication usage
Study: 15013946
Drug: Peptide YY3-36
Normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide YY3-36 (PYY3-36) infusion
Study: 11762428
Drug: Antidepressant discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant discontinuation during week 8 of 12-week group CBT treatment
Study: 9826883
Drug: Bath temperature
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bath temperature of 37 degrees C (98.6 degrees F) with UVA doses ranging from 0.5 to 5.5 J/cm2
Study: 2913139
Drug: Theophylline (serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (serum levels of 10 to 20 mg/L)
Study: 1215448
Drug: Caffeine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (300 mg/70 kg) + Ethanol (0.75 g/kg)
Study: 27311739
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (VR-based motivational visuomotor feedback training with levodopa)
Study: 25302624
Drug: CZP 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZP 200 mg and 400 mg
Study: 25302624
Drug: CZP 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZP 200 mg, 400 mg, and placebo
Study: 14724869
Drug: Topical triple
Normalized name: Triple Paste Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical triple antibiotic ointment (TAO)
Study: 8082050
Drug: 1 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/day of elemental calcium in the form of calcium pidolate
Study: 28799056
Drug: Single-dose botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose botulinum toxin type A (BTX-A) injection of 70 to 100 U
Study: 28799056
Drug: Repeated-dose botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated-dose botulinum toxin type A (BTX-A) injection of 50 to 70 U initially, followed by another of equal volume 2 weeks later
Study: 21164169
Drug: DDAVP (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDAVP (1 μg/kg, intravenous)
Study: 19552493
Drug: Post-fracture use
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-fracture use of prescribed calcium plus vitamin D supplements
Study: 19552493
Drug: Post-fracture use
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-fracture use of anti-osteoporotic drugs concomitantly with calcium plus vitamin D
Study: 19552493
Drug: Neither anti-osteoporotic
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither anti-osteoporotic drugs nor prescribed calcium and vitamin D
Study: 15280750
Drug: p-GlcNAc patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: p-GlcNAc patch
Study: 11552913
Drug: Nitazoxanide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide (100 mg b.d. for age 2-3 years; 200 mg b.d. for age 4-11 years)
Study: 11552913
Drug: Metronidazole (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (125 mg b.d. for age 2-5 years; 250 mg b.d. for age 6-11 years)
Study: 8998124
Drug: Low-dose recombinant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose recombinant human growth hormone (0.5 international units/kg per week)
Study: 29301450
Drug: SonoVue (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SonoVue (1.5 ml) before HIFU ablation
Study: 29301450
Drug: Saline (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (1.5 ml) before HIFU ablation
Study: 25586282
Drug: Levosimendan (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (loading dose of 15 μg/kg/min for 20 minutes, maintenance dose of 0.2 μg/kg/min for 6 hours before anesthetic induction)
Study: 25586282
Drug: Dopamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine (10 μg/kg/min) and/or dobutamine (10 μg/kg/min) during weaning from cardiopulmonary bypass
Study: 15562385
Drug: Alendronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (5 mg/d)
Study: 12569285
Drug: Hypoxic pelvic
Normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoxic pelvic and limb perfusion with 50 mg/m² of melphalan
Study: 12569285
Drug: Hypoxic pelvic
Normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoxic pelvic and limb perfusion with 50 mg/m² of melphalan and 25 mg/m² of mitomycin C
Study: 8558148
Drug: Entacapone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entacapone (200 mg) with levodopa
Study: 30002865
Drug: AbobotulinumtoxinA injections
Normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: AbobotulinumtoxinA injections
Study: 23577077
Drug: Oxycodone at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone at a fixed dose with increasing pregabalin doses (Arm A)
Study: 23577077
Drug: Pregabalin at
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin at a fixed dose with increasing oxycodone doses (Arm B)
Study: 18955945
Drug: Ziprasidone, median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone, median dose 120 mg/day at endpoint
Study: 12814389
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (n = 30)
Study: 10770814
Drug: Elective anti-pseudomonal
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elective anti-pseudomonal antibiotic treatment (4 treatments per year)
Study: 10770814
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment (3 treatments per year)
Study: 1632252
Drug: Erythromycin 0.5
Normalized name: ERYTHROMYCIN 0.5% OINT,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 0.5 g x 2
Study: 6742612
Drug: Methylprednisolone (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (16 mg/day given orally for 7 days)
Study: 30562392
Drug: Magne B6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magne B6 (Mg–vitamin B6); daily dose 300 mg magnesium and 30 mg vitamin B6
Study: 30562392
Drug: Magnespasmyl (Mg);
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnespasmyl (Mg); daily dose 300 mg magnesium
Study: 30562392
Drug: Magne B6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magne B6 (Mg–vitamin B6)
Study: 30562392
Drug: Magnespasmyl (Mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnespasmyl (Mg)
Study: 25599775
Drug: Ketamine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine + Propofol (0.5 mg/kg ketamine + 1 mg/kg propofol)
Study: 25599775
Drug: Alfentanil +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil + Propofol (10 mg/kg alfentanil + 1 mg/kg propofol)
Study: 11860726
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g dried plums
Study: 11860726
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g dried apples
Study: 10103297
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (250 microg/dose)
Study: 10103297
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (1 mL/dose)
Study: 6137307
Drug: Leucine infusion
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine infusion (300 mumol/min for 150 min)
Study: 6137307
Drug: Leucine plus
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine plus glucose infusion (2.2 mmol/min)
Study: 6137307
Drug: Leucine, somatostatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucine, somatostatin (7 micrograms/min) and glucagon (1 ng/min) infusion
Study: 29793558
Drug: Specialised Treatment
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialised Treatment for Severe Bodily Distress Syndromes (STreSS)
Study: 23975354
Drug: Acute treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute treatment for adolescent depression for 12 weeks followed by an additional 12 weeks of treatment.
Study: 22180621
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment (IT) - 36 weeks of antiretrovirals
Study: 22180621
Drug: Deferred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred treatment (DT) - no treatment initially